Neonatal, tissue-specific stem cells for next-generation cell therapies

With burgeoning research into cell-based therapies, Longboat Amniotics has developed a novel process for the retrieval and processing of tissue-specific neonatal quality stem cells from amniotic fluid.

Like Comment
Page of
Go to the profile of Longboat Amniotics

Longboat Amniotics

Longboat Amniotics was born out of the discovery of novel stem cells in full term amniotic fluid at the renowned Lund University. Research on these cells has demonstrated a number of unique properties in them, highlighting their extraordinary suitability for medical applications. These properties, in combination with safe collection, ethical agreeability and high cell counts harbour the promise of the exciting journey we have started pushing medical boundaries. Our ultimate vision is to contribute to the successful treatment of serious human diseases by providing the very best cells for various regenerative medical applications. The fact that our cells are of neonatal source (and safely retrieved from the amniotic fluid from C-sections) means that they have greater genome integrity. And also other positive attributes of the neonatal source of our cells we suggest will make them superior to traditional sources of stem cells that are currently in therapeutic use.

No comments yet.